Prostate Cancer - US Drug Forecast and Market Analysis to 2023
The US is the largest prostate cancer market among the countries covered in this report, and will remain so through the forecast period. The US' dominance of the prostate cancer market is due to the high incidence of the disease, the high drug treatment rate, and higher drug prices compared with all the other markets. Additional factors that will drive growth of the US prostate cancer market include the increasing incidence of prostate cancer as the population ages, increased sales resulting from the launch of eight new premium-priced pipeline products during the forecast period, and the label extension of Xtandi into the nmCRPC and hormone-sensitive prostate cancer patient populations.
• Overview of Prostate Cancer including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for the top drugs in the US from 2013-2023.
• Analysis of the impact of key events as well the drivers and restraints affecting the US Prostate Cancer market.
You May Also Like